JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Intranasal Esketamine for Treatment-Resistant Depression

Peter Roy‐Byrne

Journal watch January 16, 2018 DOI: 10.1056/nejm-jw.na45881 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Peer reviewed
Topics	Depression Esketamine

Abstract

With limited medication options for treatment-resistant depression, patients often turn to transcranial magnetic stimulation (TMS), electroconvulsive

Citations in the library

Cites 1

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression JAMA Psychiatry December 27, 2017

Explore topics

Depression Esketamine

By condition and practice

Esketamine for depression Ketamine for depression